Abstract
Authors’ Reply to “Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease”
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have